Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financi...(Tel: +1-626-456-2789 Email: elain...)

Date:8/14/2009

Tel: +1-626-456-2789 Email: elaine@biostarpharmaceuticals.com John Mattio HC International, Inc. Tel: +1-914-669-5340 Email: john.mattio@hcinternational.net Web: http://www.hcinternational.net - FINANCIAL TABLES FOLLOW - BIOSTAR PHARMACEUTICALS, INC. CONSOLIDATED BALANCE SHEETS June 30, December 31, 2009 2008 (Unaudited) ASSETS Current Assets Cash and cash equivalents $1,946,696 $758,316 Accounts receivable 15,298,959 11,700,841 Inventories 560,522 315,745 Prepaid expenses and other receivables 5,735,741 2,926,505 Total Current Assets 23,541,918 15,701,407 Property and equipment, net 5,513,242 5,930,467 Intangible assets, net 7,202,230 7,365,765 Total Assets $36,257,390 $28,997,639 Current Liabilities Accounts payable and accrued expenses $2,305,913 $2,191,976 Customer and other deposits 2,705,470 2,592,250 Value-added tax payable 918,241 527,103 Income tax payable 1,359,276 413,205 Total Current Liabilities 7,288,900 5,724,534 Commitment Stockholders'
'/>"/>

SOURCE Biostar Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related biology technology :

1. Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT
2. Biostar Pharmaceuticals, Inc. Retains HC International, Inc. to Implement Investor Relations Program
3. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
4. Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008
5. Inverness Medical Innovations to Close Cholestech, HemoSense and BioStar Facilities
6. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
7. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
9. Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
10. Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets
11. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement